Acute adverse event signalling scheme using the Saskatchewan administrative health care utilization datafiles: Results for two benzodiazepines

Canadian Journal of Clinical Pharmacology

Volumn 6, Issue 3, 1999, Pages 159-166

  Rawson, Nigel S B ^a,b   Rawson, Maureen J ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Adverse drug reaction; Adverse event; Benzodiazepine; Postmarketing surveillance

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; LORAZEPAM;

AMNESIA; ARTICLE; COORDINATION; DATA BASE; DEPRESSION; DROWSINESS; HEALTH CARE UTILIZATION; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; NAUSEA; POSTMARKETING SURVEILLANCE; RASH; RESPIRATORY FAILURE; SIDE EFFECT; VERTIGO; VOMITING;

EID: 0032884516     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Rawson NSB. Post-marketing surveillance. In: Hansch C, Sammes PG, Taylor JB, eds. Comprehensive Medicinal Chemistry, vol 1: General Principles. Oxford: Pergamon Press, 1990:625-55.
2. Wilson AB. New surveillance schemes in the United Kingdom. In: Inman WHW, ed. Monitoring for Drug Safety. Lancaster: MTP Press, 1980:189-200.
3. Joint Commission on Prescription Drug Use. Final Report. Rockville: Joint Commission on Prescription Drug Use, 1980.
4. Gagnon D. Working in partnerships...drug review for the future. Ottawa: Health and Welfare Canada, 1992.
5. Rawson NSB, Pearce GL, Inman WHW. Prescription-event monitoring methodology and recent progress. J Clin Epidemiol 1990;43:509-22.
6. Mackay FJ, Dunn NR, Wilton LV, Pearce GL, Freemantle SN, Mann RD. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 1997;6:235-46.
7. Lane DA, Rawson NSB. Inferential problems in post-marketing surveillance. In: Berry DA, ed. Statistical Methodology in the Pharmaceutical Sciences. New York: Dekker, 1990:531-56.
8. Rawson NSB, D'Arcy C, Blackburn JL, et al. Epidemiologic research using linked computerized health care datafiles in Saskatchewan, Canada. Saskatoon: Psychiatric Pharmacoepidemiology Research Consortium Technical Report #2, 1992.
9. Rawson NSB. Health care utilization databases. Can J Clin Pharmacol 1998;5:203-4.
10. Rawson NSB, D'Arcy C. "Validity" and reliability: idealism and reality in the use of computerized health care databases for pharmacoepidemiological research. Postmarket Surveill 1991;5:31-55.
11. Rawson NSB, D'Arcy C. Assessing the validity of diagnostic information in administrative health care utilization data: experience in Saskatchewan. Pharmacoepidemiol Drug Saf 1998;7:389-98.
12. Strand LM, Downey W. Health databases in Saskatchewan. In: Strom BL, ed. Pharmacoepidemiology, 2nd edn. Chichester: Wiley, 1994:217-29.
13. Rawson NSB, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan health care datafiles. Stat Med 1995;14:2627-43.
14. Edouard L, Rawson NSB. Reliability of the recording of hysterectomy in the Saskatchewan health care system. Br J Obstet Gynaecol 1996;103:891-7.
15. Raiford DS, Gutthann SP, Rodriguez LAG. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology 1996;7:101-4.
16. Rawson NSB, Malcolm E, D'Arcy C. Reliability of the recording of schizophrenia and depressive disorder in the Saskatchewan health care datafiles. Soc Psychiatry Psychiatr Epidemiol 1997;32:191-9.
17. Rawson NSB. An acute adverse drug reaction alerting system using the Saskatchewan health datafiles. Drug Invest 1993;6:245-56.
18. Rawson NSB. Impact of pre-existing health conditions on the outcome of an adverse drug reaction alerting scheme: gastrointestinal disorders before piroxicam and sulindac therapy. Ann Pharmacother 1995;29:676-80.
19. World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death. 9th rev. Geneva: WHO, 1977.
20. Dawson GW, Jue SG, Brogden RN. Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression. Drugs 1984;27:132-47.
21. Ameer B, Greenblatt DJ. Lorazepam: a review of its clinical pharmacological properties and therapeutic uses. Drugs 1981;21:161-200.
22. Compendium of Pharmaceuticals and Specialties, 33rd edn. Ottawa: Canadian Pharmaceutical Association, 1998.
23. Cohn JB, Wilcox CS. Long-term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder. Pharmacotherapy 1984;4:93-8.
24. Edwards JG, Inman WHW, Pearce GL, Rawson NSB. Prescription-event monitoring of 10,895 patients treated with alprazolam. Br J Psychiatry 1991;158:387-92.
25. Kramer MS, Leventhal JM, Hutchinson TA, Feinstein AR. An algorithm for the operational assessment of adverse drug reactions I: background, description and instructions for use. JAMA 1979;242:623-32.
26. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
27. Lane DA, Kramer MS, Hutchinson TA, Jones JK, Naranjo C. The causality assessment of adverse drug reactions using a Bayesian approach. Pharm Med 1987;2:265-83.